Mus vs Oman: Previously treated cases tested for RR-/MDR-TB (%)
Mus
100.0%
in 2022
Oman
100.0%
in 2024
Mus rank
1st
Oman rank
1st
Previously treated cases tested for RR-/MDR-TB (%) over time
- Mus
- Oman
How they compare
Mus currently reports 100.0% against 100.0% in Oman, a difference of 0.0%.
The two have swapped places 4 times across 17 shared years of data; in 2005 it was Oman ahead.
Mus ranks 1st and Oman ranks 1st of 2 regions.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 92.0% | 100.0% | 8.0% | Oman |
| 2010s | 96.0% | 96.9% | 0.9% | Oman |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Mus or Oman?
- Mus, at 100.0% against 100.0% in Oman as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Mus and Oman?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Oman?
- 17 years are reported by both, from 2005 to 2022.
- How do Mus and Oman rank globally for previously treated cases tested for rr-/mdr-tb?
- Mus ranks 1st and Oman ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.